Cargando…

Research status on immunotherapy trials of gastric cancer

The breakthrough of immune checkpoint inhibitor (ICI) therapy has created extensive opportunities for cancer immunotherapy. Especially, the block of programmed death-1/programmed death ligand 1 (PD-L1) axis using ICIs has become a new therapeutic strategy to treat advanced gastric cancer (GC). Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Chao, Wu, Heng-Miao, Yu, Wei-Ming, Chen, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316931/
https://www.ncbi.nlm.nih.gov/pubmed/34368297
http://dx.doi.org/10.12998/wjcc.v9.i21.5782